Tempest Therapeutics, Inc. (TPST)

NASDAQ: TPST · IEX Real-Time Price · USD
3.760
-0.180 (-4.57%)
Feb 28, 2024, 1:12 PM EST - Market open
-4.57%
Market Cap 76.22M
Revenue (ttm) n/a
Net Income (ttm) -31.11M
Shares Out 19.25M
EPS (ttm) -2.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 184,401
Open 3.900
Previous Close 3.940
Day's Range 3.730 - 3.919
52-Week Range 0.170 - 9.770
Beta -2.67
Analysts Strong Buy
Price Target 20.50 (+445.21%)
Earnings Date Mar 20, 2024

About TPST

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular en... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 19
Stock Exchange NASDAQ
Ticker Symbol TPST
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for TPST stock is "Strong Buy." The 12-month stock price forecast is $20.5, which is an increase of 445.21% from the latest price.

Price Target
$20.5
(445.21% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and ...

25 days ago - GlobeNewsWire

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

BRISBANE, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and ...

3 months ago - GlobeNewsWire

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

BRISBANE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and ...

3 months ago - GlobeNewsWire

The Secrets Behind a 4000% Biotech Stock Surge

Remarkably, the stock did not have fundamentally changing news. It did not rocket higher on breaking news that would typically be associated with the whopping gains it experienced.

4 months ago - MarketBeat

Tempest Therapeutics shares end wild week with 8% drop

Shares of Tempest Therapeutics Inc. TPST, -8.54% fell more than 8% Friday to conclude a dramatic week in which the stock clocked a one-day gain of nearly 4,000%.

4 months ago - Market Watch

Tempest Therapeutics shares head back to earth after 4,000% gain

Shares of microcap oncology company Tempest Therapeutics Inc. TPST, -55.06% dropped more than 50% Thursday as investors took a breath after the stock's roughly 40-fold gain on Wednesday.

4 months ago - Market Watch

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

Biotech stocks are some of the most volatile in the market because of the regular FDA updates and mergers and acquisitions in the industry. Some of the most notable M&A events this year were Pfizer's ...

Other symbols: ANVSAVTXMTNB
4 months ago - Invezz

Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promise

Shares of Tempest Therapeutics Inc. TPST, +1942.52% soared more than 1,900% on Wednesday after the company released study results for its investigational cancer treatment TPST-1120 in patients with li...

5 months ago - Market Watch

Tempest Adopts Limited Duration Stockholder Rights Plan

BRISBANE, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and ...

5 months ago - GlobeNewsWire

Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

BRISBANE, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and ...

5 months ago - GlobeNewsWire

Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Webcasted Conference Call on Wednesday, October 11, 2023 at 8:30 a.m. ET Webcasted Conference Call on Wednesday, October 11, 2023 at 8:30 a.m. ET

5 months ago - GlobeNewsWire

Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development

BRISBANE, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and...

5 months ago - GlobeNewsWire

Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update

BRISBANE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and ...

7 months ago - GlobeNewsWire

Tempest to Present at the Jefferies Global Healthcare Conference

BRISBANE, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and i...

9 months ago - GlobeNewsWire

Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers

• Data show tumor shrinkage and prolonged disease control in both monotherapy and in combination with pembrolizumab • Oral, once-daily cancer treatment well tolerated with a manageable safety profile ...

9 months ago - GlobeNewsWire

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and i...

10 months ago - GlobeNewsWire

Tempest Reports First Quarter 2023 Financial Results and Provides Business Update

BRISBANE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and i...

10 months ago - GlobeNewsWire

Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

BRISBANE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and...

10 months ago - GlobeNewsWire

Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting

BRISBANE, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and...

10 months ago - GlobeNewsWire

Tempest Reports Year End 2022 Financial Results and Provides Business Update

BRISBANE, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and...

1 year ago - GlobeNewsWire

Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting

BRISBANE, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and...

1 year ago - GlobeNewsWire

Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company focused on developing first-in-class therapeutics that combi...

1 year ago - GlobeNewsWire

Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both ta...

1 year ago - GlobeNewsWire

Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both ta...

1 year ago - GlobeNewsWire

Tempest Reports Second Quarter 2022 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both ta...

1 year ago - GlobeNewsWire